Clinical Interest of Combining Transcriptomic and Genomic Signatures in High-Grade Serous Ovarian Cancer

Frontiers in Genetics - Switzerland
doi 10.3389/fgene.2020.00219
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

New in High Grade Serous Ovarian Cancer Treatment

Effective Pharmacotherapy
2019English

PARP Inhibitors in Platinum-Sensitive High-Grade Serous Ovarian Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2018English

Thrombocytosis and Hyperfibrinogenemia Are Predictive Factors of Clinical Outcomes in High-Grade Serous Ovarian Cancer Patients

BMC Cancer
Cancer ResearchOncologyGenetics
2016English

RNA Immune Signatures From Pan-Cancer Analysis Are Prognostic for High-Grade Serous Ovarian Cancer and Other Female Cancers

Cancers
Cancer ResearchOncology
2020English

Molecular Abnormalities in Ovarian Cancer Subtypes Other Than High-Grade Serous Carcinoma

Journal of Oncology
Oncology
2010English

Low-Stage High-Grade Serous Ovarian Carcinomas

International Journal of Gynecological Pathology
GynecologyForensic MedicinePathologyObstetrics
2016English

Proteome Profiling of Low Grade Serous Ovarian Cancer

Journal of Ovarian Research
GynecologyOncologyObstetrics
2019English

Genomic Copy Number Alterations in Serous Ovarian Cancer

2018English

Chemoresistance‑associated Alternative Splicing Signatures in Serous Ovarian Cancer

Oncology Letters
Cancer ResearchOncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy